Pembrolizumab (Keytruda) is available through the Cancer Drugs Fund. It is a possible treatment for untreated locally advanced or metastatic urothelial carcinoma in adults if:
- they cannot have cisplatin-containing chemotherapy
- their tumour expresses PD-L1 (a combined positive score of at least 10) and
- pembrolizumab is stopped at 2 years of continuous treatment or earlier if the disease has progressed.
More evidence on pembrolizumab is being collected, until November 2019. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
If you are not eligible for pembrolizumab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
NHS Choices may be a good place to find out more.
These organisations can give you advice and support:
- Action Bladder Cancer UK, 0300 302 0085
- Cancer Research UK, 0808 800 4040
- Fight Bladder Cancer, 01844 351621
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: 17 July 2018